Allena Pharmaceuticals
Naomi V. Dahl serves as the Senior Director of Medical Affairs at Allena Pharmaceuticals, Inc. since October 2020 and holds various academic positions at Rutgers (formerly UMDNJ) Robert Wood Johnson Medical School, including Adjunct Assistant Professor of Medicine and former Assistant Professor of Medicine. Previous roles at AMAG Pharmaceuticals involved serving as Director of Medical Affairs from February 2013 to October 2020, while prior experience at Watson Pharmaceuticals (now Allergan) included positions as Director of Clinical Affairs and Senior Principal Scientist in Clinical Affairs. Naomi V. Dahl has a robust background in designing and implementing late-phase clinical trials. Educational qualifications include a Pharm D from Rutgers University and a BSc in Pharmacology from the University of Bristol.
Allena Pharmaceuticals
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.